Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia

International Journal of Gynecological Cancer

Volumn 6, Issue 4, 1996, Pages 279-285

  Kohorn, E I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

actinomycin; low risk trophoblastic neoplasia

Indexed keywords

CHORIONIC GONADOTROPIN; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HYDATIDIFORM MOLE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; TREATMENT FAILURE; TROPHOBLASTIC TUMOR;

EID: 0030039169     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06040279.x     Document Type: Article

References (26)

1. World Health Organization. Gestational Trophoblastic Diseases. Report of a WHO Scientific Group, Technical Report Series 692, WHO Geneva (1983).
2. Kohorn EI. Single-agent chemotherapy for nonmetastatic gestational trophoblastic neoplasia. Perspectives for the 21st Century after three decades of use. J Reprod Med 1991; 36: 49-55.
3. Homesley HD. Development of single agent chemotherapy regimens for gestational trophoblastic disease. J Reprod Med 1994; 39: 185-92.
4. Wong LC, Choo YC, Ma HK. Oral etoposide in gestational trophoblastic disease. Cancer Treat Rep 1984; 68: 775-7.
5. Yew CC, Chan SYW, Wong LC, Ma HK. Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213). Cancer 1985; 55: 2348-55.
6. Newlands ES, Rustin GJS, Lutz J-K, et al. Chemotherapy for gestational trophoblastic tumours (GTT) may increase the incidence of second tumours and may cause a premature menopause. Proc Am Soc Clin Oncol March 1995; 14; Abstract #744.
7. Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales 1973-83. Lancet 1986; i: 673-7.
8. Kohorn EI. Evaluation of the criteria used to make the diagnosis of nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 1993; 48: 136-47.
9. Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin-D as the primary agent for gestational trophoblastic disease. Cancer 1975; 36: 863-6.
10. Petrilli ES, Morrow CP. Actinomycin D toxicity in the treatment of trophoblastic disease. A comparison of the five-day course to single-dose administration. Gynecol Oncol 1980; 9: 18-22.
11. Twiggs LB. Pulse-Actinomycin-D scheduling in nonmetastatic gestational trophoblastic neoplasia: Cost-effective chemotherapy. Gynecol Oncol 1982; 16: 190-5.
12. Petrilli ES, Twiggs LB, Blessing JA, Teng NNH. Single-dose Actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. Cancer 1987; 60: 2173-6.
13. Schlaerth JB, Morrow CP, Nalick RH, Gaddis O. Single-dose Actinomycin-D in the treatment of postmolar trophoblastic disease. Gynecol Oncol 1984; 19: 53-6.
14. Homesley HD, Blessing JA, Rettenmaier M, et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 1988; 72: 413-18.
15. Homesley HD, Blessing JA, Schlaerth J. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. A Gynecologic Oncology Group study. Gynecol Oncol 1990; 39: 305.
16. Berkowitz RS, Goldstein DP, Bernstein MR. Methotrexate infusion and folinic acid in the primary therapy of nonmetastatic gestational trophoblastic tumors. Gynecol Oncol 1990; 36: 56-9.
17. Elit L, Covens A, Osborne R, et al. High-dose methotrexate for gestational trophoblastic disease. Gynecol Oncol 1994; 54, 282-7.
18. Bagshawe KD, Dent J, Newlands ES, Begent RHJ, Rustin GJS. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989; 96: 795-802.
19. Berkowitz RS, Goldstein DP, Bernstein BFA. Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986; 23: 111-18.
20. Berkowitz RS, Goldstein DP. Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms. Obstet Gynecol 1979; 54: 725-8.
21. Smith EB, Weed JC, Tyrey L, Hammond C. Treatment of nonmetastatic gestational trophoblastic disease: Results of methotrexate alone versus methotrexate-folinic acid. Am J Obstet Gynecol 1982; 144: 88-92.
22. Wong LC, Choo YC, Ma HK. Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. Am J Obstet Gynecol 1985; 152: 59-62.
23. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976; 38: 1373-85.
24. Gleeson NC, Finan MA, Fuorica JV, et al. Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 1993; XIV: 461-5.
25. Lurain JR, Elfstrand, E. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol 1995; 172: 574-9.
26. Rotmensch J, Rosenshein N, Donehower R, Dillon M, Villar J. Plasma methotrexate levels in patients with gestational trophoblastic neoplasia treated by two methotrexate regimens. Am J Obstet Gynecol 1984; 148: 730-4.